Articles by Jill Wechsler - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jill Wechsler

Biotech Manufacturers Face New Political Landscape

Changes on Capital Hill create uncertainty for healthcare reform, drug regulation, and biomedical research.
Dec 1, 2010

Changes on Capital Hill create uncertainty for healthcare reform, drug regulation, and biomedical research.

Backing Biosimilars

Nov 11, 2010

FDA has to address multiple technical and legal issues to bring similar versions of biotech therapies to market.

Biotech Manufacturers Anticipate CER Challenges

Comparative effectiveness poses challenges for drug manufacturers.
Nov 1, 2010

Comparative effectiveness poses challenges for drug manufacturers.

Biotech Companies Gain Support for Vaccine, Countermeasure Production

A new strategy to streamline vaccine development and oversight.
Oct 1, 2010

A new strategy to streamline vaccine development and oversight.

REMS Program Challenges Manufacturers, Providers

Too many REMS cause headaches for doctors and the industry.
Sep 1, 2010

Too many REMS cause headaches for doctors and the industry.

Manufacturing Compliance in the Spotlight

Plant closures, product recalls prompt FDA re-evaluation of GMP enforcement efforts.
Aug 1, 2010

Plant closures, product recalls prompt FDA re-evaluation of GMP enforcement efforts.

FDA Seeks Transparency in Data and Decisions

More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.
Jul 1, 2010

More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.

Manufacturers, FDA Seek to Secure Supply Chains

International outsourcing and rising theft spur regulatory action and manufacturer oversight.
Jun 1, 2010

International outsourcing and rising theft spur regulatory action and manufacturer oversight.

Healthcare Reform Expands Coverage, Promotes Innovation

Broader benefits and biosimilars will offset hefty fees and discounts while preserving R&D incentives.
May 1, 2010

Broader benefits and biosimilars will offset hefty fees and discounts while preserving R&D incentives.

ADVERTISEMENT

ADVERTISEMENT

Click here